GoodRx Holdings (GDRX) Change in Accured Expenses (2019 - 2026)

GoodRx Holdings has disclosed Change in Accured Expenses across 8 years of filings, most recently posting $14.3 million for Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 11.3% year-over-year to $14.3 million; the TTM figure through Jun 2026 stood at $12.5 million (down 7.83% YoY), while the FY2025 annual figure was $2.0 million, down 79.96% from the prior year.
• Change in Accured Expenses came in at $14.3 million for Q2 2026 at GoodRx Holdings, up from $1.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $36.6 million in Q3 2025 to a low of -$40.2 million in Q4 2025.
• Average Change in Accured Expenses over 5 years is $2.4 million, with a median of $1.5 million recorded in 2023.
• Year-over-year, Change in Accured Expenses sank 4108.62% in 2022 and surged 1438.99% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$14.4 million in 2022, then jumped by 66.46% to -$4.8 million in 2023, then sank by 104.79% to -$9.9 million in 2024, then slumped by 307.64% to -$40.2 million in 2025, then soared by 135.6% to $14.3 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $14.3 million in Q2 2026, $1.7 million in Q1 2026, and -$40.2 million in Q4 2025.